Nasolabial FoldsNCT06984835
Safety and Effectiveness of ELLANSÉ®-S Dermal Filler in the Treatment of Nasolabial Folds
A study testing Ellanse S and Calcium Hydroxylapatite-based filler in people with Nasolabial Folds, run by AQTIS Medical B.V. at 7 sites in United States.
Trial summary
The study will be a prospective, randomized, multi-center, split-face, controlled, double-blind clinical trial to evaluate the safety and effectiveness of ELLANSÉ®-S for the treatment of NLFs. Subjects will be randomized to receive treatment (ELLANSÉ®-S) in one NLF and control (Radiesse®) in the contralateral NLF. Read more about this study
- Who is it for?
- Ages 22 years and older
- Conditions the study is for
- Nasolabial Folds
- What is being tested?
- Ellanse S and Calcium Hydroxylapatite-based filler
- Type of treatment
- Injection or infusion, Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 126 participants
- Where
- 7 sitesUnited States
- Study dates
- 31 Mar 2025to Dec 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 22 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Only subjects meeting all of the following inclusion criteria will be considered for study enrollment:
- Subject is male or female aged at least 22 years.
- Subject has bilateral moderate or severe (symmetric grade 3 or 4) NLFs on the WSRS as scored by the treating investigator.
- Subject is willing to abstain from other facial aesthetic procedures in the lower face including the NLFs through the study period (up to the final follow-up visit, depending on retreatment) which could interfere with treatment outcomes (e.g. facial fillers, skin laser and radiofrequency therapy such as Thermage, chemical re-surfacing, dermabrasion, Botox injections, aesthetic facial surgery, other facial treatments in the NLFs).
- Subject understands and accepts the obligation to present for all scheduled follow-up visits and is logistically able to meet all study requirements.
- Subject with facial hair which may obstruct the assessment of the treatment area, must be agreeable with non-laser removal of facial hair prior to assessment visits.
Show all 9Show fewer
- Subject agrees to avoid dental procedures (surgery, implants, dental work) for 3 weeks after any treatment.
- Subject is willing to provide written informed consent for their participation in the study.
- Subject has best corrected visual acuity of 20/40 or better (in each eye), and have normal confrontational visual fields, and normal extraocular motility.
Who cannot join
- Subjects having any of the following criteria, either at screening or at baseline, will not be included in the study:
- Subject is a female of childbearing potential (e.g., not postmenopausal for at least one year or has not had a hysterectomy or tubal ligation) not using medically effective birth control (e.g., hormonal methods in use at least 30 days prior to injection or barrier methods such as condom and spermicide in use at least 14 days prior to injection) or is pregnant, lactating, or plans to become pregnant during the study.
- Subject has participated in a clinical study in which an investigational device or drug was received in the 30 days prior to screening or plans to enroll in such a study during the course of the current study.
- Subject is an employee or direct relative of an employee of the investigational site or study sponsor.
- Subject has received surgery in the NLFs.
- Subject has received facial threads or autologous fat injections in the face.
Show all 32Show fewer
- Subject has a serious or progressive disease, which, in the investigator's judgment, puts the subject at undue risk (e.g., uncontrolled diabetes, autoimmune disease, cardiac pathologies).
- Subject has an acute inflammatory process or infection, or history of chronic or recurrent infection or inflammation with the potential to interfere with the study results or increase the risk of adverse events.
- Subject has a disorder that may impact wound healing such as connective tissue or immunosuppressive disorder.
- Subject has a history of precancerous lesions/skin malignancies.
- Subject has had an active skin disease within the past 6 months.
- Subject has scars, infection, rosacea, herpes, acne, blotches or other pathology in the NLFs that in the Investigator's opinion will affect evaluation or treatment.
- Subject has facial hair covering the nasolabial folds that they are unwilling to remove for study assessments.
- Subject has a past history of systemic streptococcal disease or an active streptococcus infection.
- Subject has had a COVID-19 vaccine within 2 weeks of scheduled injections or plans to receive one 3 weeks after any study injection.
- Subject was ill with a virus (SARS, COVID, flu) within 2 weeks of scheduled injection.
- Subject is predisposed to keloidosis or hypertrophic scarring.
- Subject has a known history of hyper- or hypo-pigmentation in the NLFs.
- Subject with known allergy to poly (ε-caprolactone), phosphate buffered saline, glycerine, calcium hydroxylapatite (CaHA), or sodium carboxymethylcellulose.
- Subject has a known history of multiple allergies, allergic/anaphylactic reactions including hypersensitivity to lidocaine or anesthetics of the amide type.
- Subject has a known bleeding disorder.
- Subject has received within the past 2 weeks or plans to receive up to 1 week after treatment high-dose Vitamin E, aspirin, anti-inflammatories, antiplatelets, thrombolytics or any other medication that could increase the risk of bleeding.
- Subject has received any medication which, in the judgement of the investigator, may interfere with the study objectives.
- Subject has received within the past 12 months or plans to receive during the study any injections outside of those in the study protocol including non-permanent fillers (e.g., hyaluronic acid) or neurotoxin on the face below cheekbone (forehead is acceptable).
- Subject has received at any time or plans to receive during the study a permanent filler (e.g., PMMA, silicone) on the face below the cheekbone.
- Subject has received within the past 24 months or plans to receive during the study a semi-permanent or long last filler (e.g. polylactic acid or calcium hydroxylapatite CaHA) on the face.
- Subject has received within the past 6 months or plans to receive during the study dermal resurfacing procedures or non-invasive skin tightening or energy based or mechanical or chemical aesthetic procedure on the face.
- Subject has received in the past 4 weeks or plans to receive during the study prescription facial wrinkle therapies (tretinoin), topical steroids,
- Subject has received within the past 2 weeks skin irritating topical preparations, or self-tanning agents on the face.
- Subject has received within the past 6 months systemic retinoids.
- Subject has received within the past 3 months systemic steroids or chemotherapy or immunosuppressive agents.
- Subject has a known history of ongoing rapid weight loss/gain or plans to begin a weight loss program during the study (5% of body weight).
Trial locations and contacts
7 sites in 1 country.
7 sites in 1 country
United States7 sites
Skincare Physicians
Chestnut Hill, Massachusetts, 02467
Clinical Testing of Beverly Hills
Encino, California, 91436
Callender Center for Clinical Research
Glenn Dale, Maryland, 20769
Skin Research Institute LLC
Miami, Florida, 33146
Investigate MD
Scottsdale, Arizona, 86260
Advanced Dermatology of Michigan
Warren, Michigan, 48088
DMR Research, PLLC
Westport, Connecticut, 06880
About this study
Official title: A Prospective, Multi-Center, Randomized, Controlled, Double-Blind, Split-Face Study of the Safety and Effectiveness of ELLANSÉ®-S Dermal Filler in the Treatment of Nasolabial Folds
The study will be a prospective, randomized, multi-center, split-face, controlled, double-blind clinical trial to evaluate the safety and effectiveness of ELLANSÉ®-S for the treatment of NLFs. Subjects will be randomized to receive treatment (ELLANSÉ®-S) in one NLF and control (Radiesse®) in the contralateral NLF. A total of 126 subjects will be treated. The control and test articles will be supplied in sterile ready-to-use, pre-filled syringes. Initial treatment and any 4-week touch-up will be done consistent with initial randomization. Any retreatment(s) in either NLF will be with ELLANSÉ®-S.
Subjects who meet Inclusion/Exclusion criteria will receive an initial treatment, an optional touch up at the 4-week visit, and may be eligible to receive retreatment at either 12 or 18 months after treatment (determined by when the fold has returned to baseline score, or the fold has lost at least 1 point on the Wrinkle Severity Rating Scale (WSRS) from optimal improvement). Retreatment to one side is allowed if only one side qualifies, but the other side may not be retreated at a later visit. If retreatment occurs, the subject may also be eligible to receive an optional touch up at the 4-week follow up visit. If a touch up occurs after the initial or retreatment injection, the subject will return for an additional safety visit 2 weeks after each injection. A week 4 safety visit will occur after retreatment touch-up. Primary effectiveness will be assessed at 6 months. All subjects will be followed for a minimum of 24 months after the initial treatment phase. After each injection, subjects will be contacted by telephone call/email after 72 hours and will return for a safety visit 2 weeks after treatment. At the week 4 visit, subjects will be assessed for a touch up. If a touch up is indicated as determined by the investigator, the investigator will use the same material as that used for initial treatment for the respective side. In addition, subjects will be seen at 6 weeks 3, 6, 9, 12, 18, and 24 months (from the end of the initial treatment phase). Subjects receiving a retreatment (at 12 or 18 months after treatment) will return for additional safety visits at 2 weeks and 3 and 6 months after this retreatment (the 6 month coincides with regularly scheduled visit). Subjects will have the option of a retreatment touch up injection at 4 weeks after retreatment, and if they do will have another call at 72hrs and a week 2 safety visit.
Read more
The validated Wrinkle Severity Rating Scale will be used for assessment of the primary effectiveness endpoint (1). Assessment of the secondary effectiveness endpoints will include use of WSRS, the Global Aesthetic Improvement Scale (GAIS), VAS pain assessment, the validated FACE-Q Appraisal of Nasolabial Folds Questionnaire, the FACE-Q Satisfaction with Treatment Outcome Scale and the FACE-Q Age Appraisal VAS.
The study will last approximately 30 months. All subjects will be recruited within approximately 6 months after the recruitment of the first subject and followed for a minimum of 24 months after the initial treatment visit. Subjects receiving a retreatment (at 12 or 18 months) will receive a telephone call/email 72 hours after retreatment and they will return for an additional safety visit 2 weeks after retreatment. Subjects may receive a retreatment touch up at 4 weeks after retreatment, and if touched up, will have safety visits at 2 and 4 weeks. All retreated subjects will also be asked to attend month 3 and month 6 safety visits. The 6-month safety visit will correspond with the next study visit (e.g., 18 month or 24-month visit depending on when they are reinjected)
126 male and female subjects will be enrolled. This enrollment number accounts for a 20% attrition rate, to ensure an adequate safety population for long-term follow-up, and a Per Protocol Set (PPS) of at least 101 NLFs per treatment arm. At least 20% of treated subjects will have Fitzpatrick Skin Types IV, V, and VI. Of these, at least, 10% will be Type IV, 5% Type V and 5% Type VI. The investigative sites will be encouraged to enroll both male and female subjects. In addition, up to 2 non-randomized, non-split-face run-in subjects will be treated with ELLANSÉ®-S by each investigator to allow the investigator to become familiar with injection characteristics. This run-in cohort will be required to meet all study inclusion/exclusion criteria and will be followed in the same manner as the non-run-in cohort. Up to seven US sites will participate.
- Conditions
- Nasolabial Folds
- Being tested
- Ellanse S, Calcium Hydroxylapatite-based filler
- Keywords
- nasolabial folds, NLF, NLFs, dermal filler, wrinkle, correction, wrinkles, Ellanse, Ellanse S, polycaprolactone, PCL, microspheres, resorbable
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Ellanse SDevice
Ellanse S polycaprolactone and carboxymethylcelluose gel based dermal filler syringe
Calcium Hydroxylapatite-based fillerDevice
Calcium Hydroxylapatite and carboxymethylcellulose based filler
| Study group | Role | What they receive |
|---|---|---|
| Ellanse S | Experimental | Polycaprolactone and carboxymethylcellulose gel based dermal filler Receives: Device: Ellanse S |
| Calcium Hydroxylapatite | Active comparator | Calcium Hydroxylapatite and carboxymethylcellulose gel based dermal filler Receives: Device: Calcium Hydroxylapatite-based filler |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mean Change in NLF WSRS score from baseline at 6 months by a live, masked reviewer
The primary effectiveness endpoint uses the 6-month and baseline Wrinkle Severity Rating Scale (WSRS) scores as determined by a live, masked reviewer. The change from baseline on the WSRS at 6 months of NLFs in the ELLANSÉ®-S treatment arm will be compared to that of NLFs in the Radiesse® control arm. The statistical objective is to demonstrate non-inferiority of WSRS improvement in the NLF indication of ELLANSÉ®-S to Radiesse®.
Note: the WSRS provides 5 scoring options from 1 Absent to 5 Extreme. A lower score is a better clinical outcome.
Measured: 6 months
Secondary outcomes (16)
Difference in mean change from baseline on the Wrinkle Severity Rating Scale (WSRS) at 12 months as rated by a live, masked reviewer
Difference in mean change from baseline on the Wrinkle Severity Rating Scale (WSRS) at 12 months as rated by a live, masked reviewer Note: the WSRS provides 5 scoring options from 1 Absent to 5 Extreme. A lower score is a better clinical outcome.
Measured: 12 months
Global Aesthetic Improvement Scale (GAIS) response rate at 6 months as rated by the live, masked reviewer
Global Aesthetic Improvement Scale (GAIS) response rate at 6 months as rated by the live, masked reviewer Note: There are 5 scoring options ranging from from "Very Much Improved" to "Worse"
Measured: 6 months
Difference in mean change in total score on the FACE-Q Appraisal of Nasolabial Folds Questionnaire at 6 months.
Difference in mean change in total score on the FACE-Q Appraisal of Nasolabial Folds Questionnaire at 6 months.
Note: 4 responses can be chosen; not at all (1), a little (2), moderately (3) and extremely (4), a lower score is a better clinical outcome
Measured: 6 months
Difference in mean change in total score on the FACE-Q Appraisal of Nasolabial Folds Questionnaire at 12 months
Difference in mean change in total score on the FACE-Q Appraisal of Nasolabial Folds Questionnaire at 12 months.
Note: 4 responses can be chosen; not at all (1), a little (2), moderately (3) and extremely (4), a lower score is a better clinical outcome
Measured: 12 months
Difference in mean change from baseline on the Wrinkle Severity Rating Scale (WSRS) at 18 months as rated by a live, masked reviewer.
Difference in mean change from baseline on the Wrinkle Severity Rating Scale (WSRS) at 18 months as rated by a live, masked reviewer.
Note: the WSRS provides 5 scoring options from 1 Absent to 5 Extreme. A lower score is a better clinical outcome.
Measured: 18 months
Individual endpoints at each time point of, 6 weeks, 3, 6, 9, 12, and 18, and 24 months for responders on the Wrinkle Severity Rating Scale (WSRS), as determined by a live, masked reviewer.ry Endpoint 1
Individual endpoints at each time point of, 6 weeks, 3, 6, 9, 12, and 18, and 24 months for responders on the Wrinkle Severity Rating Scale (WSRS), as determined by a live, masked reviewer.
Note: the WSRS provides 5 scoring options from 1 Absent to 5 Extreme. A lower score is a better clinical outcome.
Measured: 6 weeks, 3, 6, 9, 12, 18 and 24 months
Individual endpoints at each time point of 6 weeks, 3, 9, and 24 months for change from baseline on the Wrinkle Severity Rating Scale (WSRS), as determined by a live, masked reviewer.
Individual endpoints at each time point of 6 weeks, 3, 9, and 24 months for change from baseline on the Wrinkle Severity Rating Scale (WSRS), as determined by a live, masked reviewer.
Note: the WSRS provides 5 scoring options from 1 Absent to 5 Extreme. A lower score is a better clinical outcome.
Measured: 6 weeks, 3, 9 and 24 months
Individual endpoints at 6 weeks, 3, 6, 9, 12, 18, & 24 months for the comparative improvement on the Wrinkle Severity Rating Scale (WSRS) by subject of NLFs in the ELLANSÉ®-S arm to NLFs in the Radiesse® arm, as determined by a live, masked evaluator
Individual endpoints at each time point of 6 weeks, 3, 6, 9, 12, 18, and 24 months for the comparative improvement on the Wrinkle Severity Rating Scale (WSRS) by subject of NLFs in the ELLANSÉ®-S treatment arm to NLFs in the Radiesse® arm, as determined by a live, masked evaluator.
Note: the WSRS provides 5 scoring options from 1 Absent to 5 Extreme. A lower score is a better clinical outcome.
Measured: 6 weeks, 3, 6, 9, 12, 18 and 24 months
Individual endpoints at each time point of 6 weeks, 3, 6, 9, 12, 18, and 24 months for change from baseline on the Wrinkle Severity Rating Scale (WSRS), as determined by a blinded photographic review panel
Individual endpoints at each time point of 6 weeks, 3, 6, 9, 12, 18, and 24 months for change from baseline on the Wrinkle Severity Rating Scale (WSRS), as determined by a blinded photographic review panel.
Note: the WSRS provides 5 scoring options from 1 Absent to 5 Extreme. A lower score is a better clinical outcome.
Measured: 6 weeks, 3, 6, 9, 12, 18 and 24 months
Individual endpoints at 6 weeks, 3, 6, 9, 12, 18, & 24 months for the proportion of NLFs in the ELLANSÉ®-S arm compared to NLFs in the Radiesse® arm with ≥1 point improvement from baseline on the WSRS as determined by a blinded photographic review panel
Individual endpoints at each time point of 6 weeks, 3, 6, 9, 12, 18, and 24 months for the proportion of NLFs in the ELLANSÉ®-S treatment arm compared to that of NLFs in the Radiesse® arm with ≥1 point improvement from baseline on the Wrinkle Severity Rating Scale (WSRS), as determined by a blinded photographic review panel.
Note: the WSRS provides 5 scoring options from 1 Absent to 5 Extreme. A lower score is a better clinical outcome.
Measured: 6 weeks, 3, 9, 12, 18 and 24 months
Individual endpoints at each time point of 6 weeks, 3, 6, 9, 12, 18, and 24 months for GAIS scores for ELLANSÉ®-S and Radiesse®. Individual endpoints for each rater type, as rated by: 1) Live masked evaluator 2) Treating investigator 3) The study subject
Individual endpoints at each time point of 6 weeks, 3, 6, 9, 12, 18, and 24 months for GAIS scores for ELLANSÉ®-S and Radiesse®. Individual endpoints for each rater type, as rated by:
- Live, masked evaluator (excluding the 6 month),
- treating investigator;
- and the study subject.
Measured: 6 weeks, 3, 6, 9, 12, 18 and 24 months
Individual endpoints at each time point of 6 weeks, 3, 9, 18, and 24 months for change from baseline for ELLANSÉ®-S and Radiesse® on the Subject FACE-Q Appraisal of Nasolabial Folds Questionnaire
Individual endpoints at each time point of 6 weeks, 3, 9, 18, and 24 months for change from baseline for ELLANSÉ®-S and Radiesse® on the Subject FACE-Q Appraisal of Nasolabial Folds Questionnaire.
Note: 4 responses can be chosen; not at all (1), a little (2), moderately (3) and extremely (4), a lower score is a better clinical outcome
Measured: 6 weeks, 3, 9, 12, 18 and 24 months
Individual endpoints at each time point of 6 and 12 months for change from baseline for ELLANSÉ®-S and Radiesse® on the Subject FACE-Q Satisfaction with Outcome Scale
Individual endpoints at each time point of 6 and 12 months for change from baseline for ELLANSÉ®-S and Radiesse® on the Subject FACE-Q Satisfaction with Outcome Scale.
Note: 4 responses can be chosen; definitely disagree (1), somewhat disagree (2) somewhat agree (3) and definitely agree (4); a higher score is a better clinical outcome
Measured: 6 and 12 months
Visual Analogue Scale (VAS) pain assessment in NLFs treated with ELLANSÉ®-S compared to NLFs treated with Radiesse® at initial injection
Visual Analogue Scale (VAS) pain assessment in NLFs treated with ELLANSÉ®-S compared to NLFs treated with Radiesse® at initial injection.
Note: the scale ranges from 0 - no pain to 10 - worst pain with 0.5 point increments
Measured: Baseline, 4 week post injection touch up visits, optional 12 month retreatment, optional 18 month retreatment
Duration of treatment effect as measured on the Wrinkle Severity Rating Scale (WSRS) by ≥1 point improvement, for those NLFs that did not receive retreatment prior to the assessment time point at 18 and 24 months.
Duration of treatment effect as measured on the Wrinkle Severity Rating Scale (WSRS) by ≥1 point improvement, for those NLFs that did not receive retreatment prior to the assessment time point at 18 and 24 months.
Note: the WSRS provides 5 scoring options from 1 Absent to 5 Extreme. A lower score is a better clinical outcome.
Time Frame: 6 weeks, 3, 9, 12, 18 and 24 months
Measured: 18 and 24 months
Duration of treatment effect as measured on the Wrinkle Severity Rating Scale (WSRS) by ≥1 point improvement, for those NLFs that did not receive retreatment prior to the assessment time point at 18 and 24 months.
Time until return to baseline on the Wrinkle Severity Rating Scale (WSRS) for NLFs in the ELLANSÉ®-S treatment arm compared to that of NLFs in the Radiesse® arm.
Note: the WSRS provides 5 scoring options from 1 Absent to 5 Extreme. A lower score is a better clinical outcome.
Measured: Up to 24 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 May 2025
- Study start31 Mar 2025
- Primary completionAug 2026 (estimated)
- Study completionDec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Nasolabial FoldsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- The study is a "split face" design; subjects will be treated in one nasolabial fold on one side of the face with one treatment device and with the comparator device in the nasolabial fold on the other side
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 126 participants (estimated)
Sponsor and investigators
- Lead sponsor
- AQTIS Medical B.V.
- Sponsor type
- University, hospital or other
- Collaborators
- Sinclair Pharmaceuticals Limited
- Responsible party
- Sponsor
- Investigators
- Jeremy B Green, Principal investigator, Skin Research Institute LLC
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06984835
- Sponsor's protocol ID
- SES001
- Status last verified
- Jul 2026
- First submitted
- 28 Apr 2025
- Last updated
- 21 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 21 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective, Multi-Center, Randomized, Controlled, Double-Blind, Split-Face Study of the Safety and Effectiveness of ELLANSÉ®-S Dermal Filler in the Treatment of Nasolabial Folds
- ClinicalTrials.gov ID
- NCT06984835
- Acronym / sponsor ID
- SES001
- Conditions
- Nasolabial Folds
- Keywords
- nasolabial folds, NLF, NLFs, dermal filler, wrinkle, correction, wrinkles, Ellanse
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 126 participants (estimated)
- Lead sponsor
- AQTIS Medical B.V.University, hospital or other
- Collaborators
- Sinclair Pharmaceuticals Limited
- Study start
- 31 Mar 2025 (actual)
- Primary completion
- Aug 2026 (estimated)
- Study completion
- Dec 2027 (estimated)
- First posted
- 22 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study will be a prospective, randomized, multi-center, split-face, controlled, double-blind clinical trial to evaluate the safety and effectiveness of ELLANSÉ®-S for the treatment of NLFs. Subjects will be randomized to receive treatment (ELLANSÉ®-S) in one NLF and control (Radiesse®) in the contralateral NLF. A total of 126 subjects will be treated. The control and test articles will be supplied in sterile ready-to-use, pre-filled syringes. Initial treatment and any 4-week touch-up will be done consistent with initial randomization. Any retreatment(s) in either NLF will be with ELLANSÉ®-S.
Subjects who meet Inclusion/Exclusion criteria will receive an initial treatment, an optional touch up at the 4-week visit, and may be eligible to receive retreatment at either 12 or 18 months after treatment (determined by when the fold has returned to baseline score, or the fold has lost at least 1 point on the Wrinkle Severity Rating Scale (WSRS) from optimal improvement). Retreatment to one side is allowed if only one side qualifies, but the other side may not be retreated at a later visit. If retreatment occurs, the subject may also be eligible to receive an optional touch up at the 4-week follow up visit. If a touch up occurs after the initial or retreatment injection, the subject will return for an additional safety visit 2 weeks after each injection. A week 4 safety visit will occur after retreatment touch-up. Primary effectiveness will be assessed at 6 months. All subjects will be followed for a minimum of 24 months after the initial treatment phase. After each injection, subjects will be contacted by telephone call/email after 72 hours and will return for a safety visit 2 weeks after treatment. At the week 4 visit, subjects will be assessed for a touch up. If a touch up is indicated as determined by the investigator, the investigator will use the same material as that used for initial treatment for the respective side. In addition, subjects will be seen at 6 weeks 3, 6, 9, 12, 18, and 24 months (from the end of the initial treatment phase). Subjects receiving a retreatment (at 12 or 18 months after treatment) will return for additional safety visits at 2 weeks and 3 and 6 months after this retreatment (the 6 month coincides with regularly scheduled visit). Subjects will have the option of a retreatment touch up injection at 4 weeks after retreatment, and if they do will have another call at 72hrs and a week 2 safety visit.
The validated Wrinkle Severity Rating Scale will be used for assessment of the primary effectiveness endpoint (1). Assessment of the secondary effectiveness endpoints will include use of WSRS, the Global Aesthetic Improvement Scale (GAIS), VAS pain assessment, the validated FACE-Q Appraisal of Nasolabial Folds Questionnaire, the FACE-Q Satisfaction with Treatment Outcome Scale and the FACE-Q Age Appraisal VAS.
The study will last approximately 30 months. All subjects will be recruited within approximately 6 months after the recruitment of the first subject and followed for a minimum of 24 months after the initial treatment visit. Subjects receiving a retreatment (at 12 or 18 months) will receive a telephone call/email 72 hours after retreatment and they will return for an additional safety visit 2 weeks after retreatment. Subjects may receive a retreatment touch up at 4 weeks after retreatment, and if touched up, will have safety visits at 2 and 4 weeks. All retreated subjects will also be asked to attend month 3 and month 6 safety visits. The 6-month safety visit will correspond with the next study visit (e.g., 18 month or 24-month visit depending on when they are reinjected)
126 male and female subjects will be enrolled. This enrollment number accounts for a 20% attrition rate, to ensure an adequate safety population for long-term follow-up, and a Per Protocol Set (PPS) of at least 101 NLFs per treatment arm. At least 20% of treated subjects will have Fitzpatrick Skin Types IV, V, and VI. Of these, at least, 10% will be Type IV, 5% Type V and 5% Type VI. The investigative sites will be encouraged to enroll both male and female subjects. In addition, up to 2 non-randomized, non-split-face run-in subjects will be treated with ELLANSÉ®-S by each investigator to allow the investigator to become familiar with injection characteristics. This run-in cohort will be required to meet all study inclusion/exclusion criteria and will be followed in the same manner as the non-run-in cohort. Up to seven US sites will participate.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
- Model description
- The study is a "split face" design; subjects will be treated in one nasolabial fold on one side of the face with one treatment device and with the comparator device in the nasolabial fold on the other side
| Arm | Type | Receives |
|---|---|---|
| Ellanse S | Experimental | Device: Ellanse SPolycaprolactone and carboxymethylcellulose gel based dermal filler |
| Calcium Hydroxylapatite | Active comparator | Device: Calcium Hydroxylapatite-based fillerCalcium Hydroxylapatite and carboxymethylcellulose gel based dermal filler |
Who may qualify
- Ages
- 22 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- Only subjects meeting all of the following inclusion criteria will be considered for study enrollment:
- Subject is male or female aged at least 22 years.
- Subject has bilateral moderate or severe (symmetric grade 3 or 4) NLFs on the WSRS as scored by the treating investigator.
- Subject is willing to abstain from other facial aesthetic procedures in the lower face including the NLFs through the study period (up to the final follow-up visit, depending on retreatment) which could interfere with treatment outcomes (e.g. facial fillers, skin laser and radiofrequency therapy such as Thermage, chemical re-surfacing, dermabrasion, Botox injections, aesthetic facial surgery, other facial treatments in the NLFs).
- Subject understands and accepts the obligation to present for all scheduled follow-up visits and is logistically able to meet all study requirements.
Key exclusion criteria (32 listed)
- Subjects having any of the following criteria, either at screening or at baseline, will not be included in the study:
- Subject is a female of childbearing potential (e.g., not postmenopausal for at least one year or has not had a hysterectomy or tubal ligation) not using medically effective birth control (e.g., hormonal methods in use at least 30 days prior to injection or barrier methods such as condom and spermicide in use at least 14 days prior to injection) or is pregnant, lactating, or plans to become pregnant during the study.
- Subject has participated in a clinical study in which an investigational device or drug was received in the 30 days prior to screening or plans to enroll in such a study during the course of the current study.
- Subject is an employee or direct relative of an employee of the investigational site or study sponsor.
- Subject has received surgery in the NLFs.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Ellanse SEllanse S polycaprolactone and carboxymethylcelluose gel based dermal filler syringe | Device | Ellanse S |
| Calcium Hydroxylapatite-based fillerCalcium Hydroxylapatite and carboxymethylcellulose based filler | Device | Calcium Hydroxylapatite |
Primary outcome
Mean Change in NLF WSRS score from baseline at 6 months by a live, masked reviewer
Time frame: 6 months
The primary effectiveness endpoint uses the 6-month and baseline Wrinkle Severity Rating Scale (WSRS) scores as determined by a live, masked reviewer. The change from baseline on the WSRS at 6 months of NLFs in the ELLANSÉ®-S treatment arm will be compared to that of NLFs in the Radiesse® control arm. The statistical objective is to demonstrate non-inferiority of WSRS improvement in the NLF indication of ELLANSÉ®-S to Radiesse®. Note: the WSRS provides 5 scoring options from 1 Absent to 5 Extreme. A lower score is a better clinical outcome.
16 secondary outcomes
Difference in mean change from baseline on the Wrinkle Severity Rating Scale (WSRS) at 12 months as rated by a live, masked reviewer
Time frame: 12 months
Global Aesthetic Improvement Scale (GAIS) response rate at 6 months as rated by the live, masked reviewer
Time frame: 6 months
Difference in mean change in total score on the FACE-Q Appraisal of Nasolabial Folds Questionnaire at 6 months.
Time frame: 6 months
Difference in mean change in total score on the FACE-Q Appraisal of Nasolabial Folds Questionnaire at 12 months
Time frame: 12 months
Difference in mean change from baseline on the Wrinkle Severity Rating Scale (WSRS) at 18 months as rated by a live, masked reviewer.
Time frame: 18 months
Individual endpoints at each time point of, 6 weeks, 3, 6, 9, 12, and 18, and 24 months for responders on the Wrinkle Severity Rating Scale (WSRS), as determined by a live, masked reviewer.ry Endpoint 1
Time frame: 6 weeks, 3, 6, 9, 12, 18 and 24 months
Individual endpoints at each time point of 6 weeks, 3, 9, and 24 months for change from baseline on the Wrinkle Severity Rating Scale (WSRS), as determined by a live, masked reviewer.
Time frame: 6 weeks, 3, 9 and 24 months
Individual endpoints at 6 weeks, 3, 6, 9, 12, 18, & 24 months for the comparative improvement on the Wrinkle Severity Rating Scale (WSRS) by subject of NLFs in the ELLANSÉ®-S arm to NLFs in the Radiesse® arm, as determined by a live, masked evaluator
Time frame: 6 weeks, 3, 6, 9, 12, 18 and 24 months
Individual endpoints at each time point of 6 weeks, 3, 6, 9, 12, 18, and 24 months for change from baseline on the Wrinkle Severity Rating Scale (WSRS), as determined by a blinded photographic review panel
Time frame: 6 weeks, 3, 6, 9, 12, 18 and 24 months
Individual endpoints at 6 weeks, 3, 6, 9, 12, 18, & 24 months for the proportion of NLFs in the ELLANSÉ®-S arm compared to NLFs in the Radiesse® arm with ≥1 point improvement from baseline on the WSRS as determined by a blinded photographic review panel
Time frame: 6 weeks, 3, 9, 12, 18 and 24 months
Individual endpoints at each time point of 6 weeks, 3, 6, 9, 12, 18, and 24 months for GAIS scores for ELLANSÉ®-S and Radiesse®. Individual endpoints for each rater type, as rated by: 1) Live masked evaluator 2) Treating investigator 3) The study subject
Time frame: 6 weeks, 3, 6, 9, 12, 18 and 24 months
Individual endpoints at each time point of 6 weeks, 3, 9, 18, and 24 months for change from baseline for ELLANSÉ®-S and Radiesse® on the Subject FACE-Q Appraisal of Nasolabial Folds Questionnaire
Time frame: 6 weeks, 3, 9, 12, 18 and 24 months
Individual endpoints at each time point of 6 and 12 months for change from baseline for ELLANSÉ®-S and Radiesse® on the Subject FACE-Q Satisfaction with Outcome Scale
Time frame: 6 and 12 months
Visual Analogue Scale (VAS) pain assessment in NLFs treated with ELLANSÉ®-S compared to NLFs treated with Radiesse® at initial injection
Time frame: Baseline, 4 week post injection touch up visits, optional 12 month retreatment, optional 18 month retreatment
Duration of treatment effect as measured on the Wrinkle Severity Rating Scale (WSRS) by ≥1 point improvement, for those NLFs that did not receive retreatment prior to the assessment time point at 18 and 24 months.
Time frame: 18 and 24 months
Duration of treatment effect as measured on the Wrinkle Severity Rating Scale (WSRS) by ≥1 point improvement, for those NLFs that did not receive retreatment prior to the assessment time point at 18 and 24 months.
Time frame: Up to 24 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Jul 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Nasolabial Folds
Recruiting
A Study to Confirm Safety and Effectiveness of RADIESSE® Injectable Implant for the Correction of Moderate to Severe Nasolabial Folds
Nasolabial Folds
Not yet recruiting
Dermal Evaluation of Facetem™ S in Nasolabial Folds Esthetics Improvement: DEFINE Study
Nasolabial Folds
Active, not recruiting
Post Market Clinical Follow up Evaluating the Performance and Safety of Juläine(TM) on Nasolabial Fold Wrinkles
Nasolabial Fold
RecruitingPhase 3
Study to Assess Adverse Events and How Effective NOA LIFT is Compared to JUVÉDERM VOLIFT With Lidocaine for the Correction of Nasolabial Folds in Adults
Nasolabial Folds
Recruiting
THE EVALUATION OF THE SAFETY AND PERFORMANCE OF AN INJECTABLE HYALURONIC ACID FILLER
Lips Enhancement Nasolabial Fold Correction Midface Volume Deficit
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jeremy B Green principal investigator
Skin Research Institute LLC
7 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Ellanse S and Calcium Hydroxylapatite-based filler in people with Nasolabial Folds, run by AQTIS Medical B.V. at 7 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 32 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 21 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 7 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mean Change in NLF WSRS score from baseline at 6 months by a live, masked reviewer (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Jul 2026.